ATH alterity therapeutics limited

Ann: Appendix 3B , page-24

  1. 6,386 Posts.
    lightbulb Created with Sketch. 1760
    I would be a little careful about chart interpretations. Fundamentals some times come into play.

    The pull back you mentioned could have been influenced by the announcement of the Prospectus for the issue of $47 million of ADR's.. This was compounded 2 weeks later with a further announcement of the delay in REACH trial results. The (up till then) rampaging SP took a huge hit over this period. I don't see such a scenerio unfolding atm.

    IMO, an Appendix 3B for the issue of a chunk of those ADR'S, is the principal risk to the SP taking a hit pre upcoming REACH results.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.2¢
Change
0.001(9.09%)
Mkt cap ! $79.88M
Open High Low Value Volume
1.1¢ 1.3¢ 1.1¢ $755.4K 64.52M

Buyers (Bids)

No. Vol. Price($)
8 5007989 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 9193829 13
View Market Depth
Last trade - 16.10pm 24/02/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.